FYB Formycon AG

DGAP-News: Formycon erhält Fördermittel für COVID-19-Arzneimittelforschung von der Bayerischen Forschungsstiftung

DGAP-News: Formycon erhält Fördermittel für COVID-19-Arzneimittelforschung von der Bayerischen Forschungsstiftung
DE
13/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Formycon AG

 PRESS RELEASE

Formycon and Zydus partner for exclusive licensing and supply agreemen...

Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a strong foundation for a successful launch of FYB206Strong early partnering interest underscores industry confidence in Formycon’s biosimilar expertise and development excellenceAgreement structure includes in total mid-teens-million-euro upfront and 2025 milestone payments, alongside additional development and regulatory m...

Martial Descoutures
  • Martial Descoutures
Martial Descoutures
  • Martial Descoutures

ResearchPool Subscriptions

Get the most out of your insights

Get in touch